Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy
Advanced Science · 2024
DOI: 10.1002/advs.202401648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Da Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350108, China. Hauptthemen laut MEDLINE: Glaucoma, Intraocular Pressure, Brimonidine Tartrate, Nanoparticles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Glaucoma Research Foundation Schaffer Grant, 4-VA Cavelier Collaborative Award., NIH HHS.
Abstract (Originalsprache)
Efficient topical drug delivery remains a significant challenge in glaucoma management. Although nanoparticle formulations offer considerable promise, their complex preparation processes, co‐delivery issues, and batch consistency have hindered their potential. A scalable fabrication strategy is developed here for preparing solid drug nanoparticles (SDNs) with enhanced drug delivery efficiency. Utilizing hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX), uniform fixed combination BM/BX SDNs are fabricated through a continuous process, improving batch‐to‐batch consistency for combined glaucoma treatment. With trehalose being used as a lyoprotectant, BM/BX SDNs can be stored as dry powder and easily reconstituted in phosphate buffered saline. Importantly, reconstituted BM/BX SDNs form clear, homogenous solutions, and exhibit negligible cytotoxicity and irritation, making them well‐suited for topical administration as eyedrops. Ex vivo and in vivo studies demonstrated that topically applied BM/BX SDNs permeate through the cornea significantly (about two fold to three fold) compared to their hydrophilic counterparts, i.e., brimonidine tartrate, and betaxolol hydrogen chloride. Notably, BM/BX SDNs displayed consistent intraocular pressure lowering effects in vivo in both normotensive rats and glaucoma mice. Collectively, this study demonstrates the potential of the scalable fabrication strategy and the resultant BM/BX SDNs for improving glaucoma management through eyedrops.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350108, China.
- Linda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, MO, 65409, USA.
- Department of Biology, University of Virginia, Charlottesville, VA, 22904, USA.
- Department of Psychology, University of Virginia, Charlottesville, VA, 22904, USA.
- Program in Fundamental Neuroscience, University of Virginia, Charlottesville, VA, 22904, USA.
ORCID-Profile: Xiaorong Liu, Hu Yang
Förderung
- NEI NIH HHS
- Glaucoma Research Foundation Schaffer Grant, 4-VA Cavelier Collaborative Award.
- NIH HHS
- National Institutes of Health
Zitieren
APA
Huang, D., Norat, P., Qi, L., Chernatynskaya, A., Cole, J. D., Mani, V. J., Xu, L., Liu, X., & Yang, H. (2024). Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy. Advanced Science. https://doi.org/10.1002/advs.202401648
Vancouver
Huang D, Norat P, Qi L, Chernatynskaya A, Cole JD, Mani VJ, et al. Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy. Advanced Science. 2024. doi:10.1002/advs.202401648
BibTeX
@article{Huang2024,
author = {Huang, Da and Norat, Pedro and Qi, Lin and Chernatynskaya, Anna and Cole, James D and Mani, Vimalin Jeyalatha and Xu, Lei and Liu, Xiaorong and Yang, Hu},
title = {Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202401648}
}
EUVIMED